Harvard Bioscience Inc (HBIO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
$8.90+1.14%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-29
Research Workspace
Put HBIO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Adjusted gross margin between 58% and 60% in fiscal year 2026: Comparison needs review.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthManagement screens weak on earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 1% on a typical day and fell roughly 45% in its worst 12-month stretch.
View RiskHBIO’s case rests on strong recent financial performance, though revenue growth has slowed to 11% year over year. That growth came with a non-GAAP loss in Q2 FY2026, and no latest release is on record. HBIO trades at 0.5× sales versus a 2.7× peer median; expectations look modest versus our view. The peer gap must be earned, and our model puts the next-quarter miss probability near 38%. Fiscal 2026 adjusted gross margin comparison needs review, so the pillar remains unverified. Peer multiples imply a price about 83% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. HBIO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering HBIO (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare HBIO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HBIO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put HBIO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Revenue Growth of 2% to 4% for FY26
Beating estimates and raising guidance supports revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Revenue Growth of 2% to 4% for FY26
Price target increase indicates confidence in revenue growth.
Threatens: Revenue Growth of 2% to 4% for FY26
Revenue growth target lowered, impacting growth outlook.
